Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation

STOCKHOLM, November 20 - Karolinska Development AB today announced that the European Investment
Fund (EIF) has entered into a co-investment agreement with the company. The
co-investment fund will be managed by Karolinska Development and used to
invest in the company's portfolio of early-stage pharmaceutical and medical
technology companies. EIF has agreed to invest 26.7 M Euros in the
co-investment fund. The agreement represents EIF's largest single investment
in the Nordic region to date.

Marketing Authorisation Application for S-1 Validated by European Medicines Agency

TOKYO, November 19 - Taiho Pharmaceutical Company, Ltd. today announced that the Company's
Marketing Authorisation Application (MAA) for S-1, proposed for the treatment
of advanced gastric cancer when combined with cisplatin, was validated by the
European Medicines Agency (EMEA). S-1 was designated as an orphan medicinal
product for the treatment of gastric cancer by the EMEA on 20 December 2007.

AMT Provides Business Update for the Third Quarter 2009

Glybera(R) Clinical Data Presented at Meeting of American Heart Association

AMSTERDAM, November 18 - Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in
the field of human gene therapy, today provides its non-audited business
update in compliance with the EU transparency directive. This report
summarizes material events and AMT's financial position for the third quarter
of 2009.

Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD)

New Report Highlights Global Economic Burden of the Disease

LONDON, November 18 - COPD Uncovered, a new report issued today reveals for the first time that
people between the ages of 40 to 65 are emerging as the new face of this
disease. Authored by Education for Health and other leading experts, the
report uncovers a new, younger majority of COPD patients(1) who are in the
prime of their career, and financially responsible for the care of their
children and aging parents. The authors call for policymakers to read the
report and challenge their thinking on how COPD should be addressed in this
critical age group who are highly depended upon by society as leading wage
earners(2,3).

Teva Launches TevaGrastim(R) (filgrastim)

LEEDS, England, November 18 - Teva UK Limited has signalled its commitment to developing biosimilar
medicines by entering the G-CSF* therapy area. The launch of its proprietary
version of filgrastim, TevaGrastim(R), marks the Company's first biosimilar*,
and represents a major addition to Teva's Hospitals portfolio.

Hard To Treat Diseases (HTDS) Mellow Hope's H1N1 Influenza A Vaccine Successful Registration in Chile

SHENZHEN, China, November 18 - Hard to Treat Diseases (HTDS; www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that they have acquired a Registration
Certificate for Mellow Hope's H1N1 Influenza A Vaccine from the government
of Chile and the first vaccines will ship in a matter of weeks.

Frost & Sullivan: The North American and Western European Biopesticides Markets Will Grow Strong Thanks to Chemical-free Crops

LONDON, November 18 - The biopesticides market in Western Europe and North America is growing
strongly. The increasing demand for chemical-free crops, paralleled by the
expansion of land for organic farming, has led to augmented usage of
biopesticides.

/C O R R E C T I O N — Education for Health/

LONDON, November 18 - In the news release, "Mainstay of the Global Workforce - 40-65 Year Olds
- Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD)" issued on 18
Nov 2009 06:30 GMT, by Education for Health over PR Newswire, we are
advised by a representative of the company that under "References:" the
hyperlink should have read:
"www.educationforhealth.org.uk/_documents/COPD_Pressrelease.pdf"
instead of:
"www.educationforhealth.org.uk/pages/_documents/COPD_Release.pdf"
as originally issued inadvertently.

/C O R R E C T I O N — Teva UK Ltd/

LEEDS, England, November 18 - In the news release, "Teva Launches TevaGrastim(R) (filgrastim)" issued on
18 Nov 2009 07:00 GMT, by Teva UK Ltd over PR Newswire, due to an omission
made by PR Newswire, we did not specify that this is a black triangle drug.
The headline should have read "Teva
Launches TevaGrastim(R) (Black Triangle Drug) (filgrastim)" rather than
"Teva Launches TevaGrastim(R) (filgrastim)" as incorrectly originally
transmitted by PR Newswire. Also, directional details to an accompanying
photo should have been included in the release. Complete, corrected release
follows:

Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products

Network of 53 Hospitals Gain Access to Masimo SET Pulse Oximeters

IRVINE, California, November 18 - Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and
Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that
Lyon, France-based Uni.H.A., one of the largest healthcare Group Purchasing
Organizations (GPO) in France, has signed a multi-year purchasing agreement
for "gold standard" Masimo SET(R) pulse oximeters. The agreement offers
preferred contract pricing to Uni.H.A.'s 53 member hospitals and provides for
more than 1,000 Masimo SET bedside pulse oximeters and 650 handheld pulse
oximeters to be purchased within four-years.

Hard to Treat Diseases' (HTDS) MMR Vaccine Passed the Chinese SFDA's 'First Drug Evaluation'

SHENZHEN, China, November 17 - Hard to Treat Diseases (HTDS; www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that its MMR vaccine (Measles, Mumps and
Rubella Combined Vaccine Live) had obtained a "pass" on its First Drug
Evaluation.

New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications

LEIDEN, The Netherlands, November 17 - Top Institute Pharma (TI Pharma) has formed a
consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and
Maastricht University to define new modalities for the treatment of
hypertension (high blood pressure) and associated vascular complications such
as heart and kidney failure, myocardial infarction and stroke. Based on novel
action mechanisms, new drugs may be discovered with the potential to prevent
vascular complications in patients with hypertension: an opportunity to
improve the quality of life for over a billion people worldwide. This
collaboration, involving 3.4 million euros, 9 new research positions, unique
materials and exchange of know-how, is scheduled to last 3 years.

Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries

Zyomyx's innovative approach enters final phase to become the world's first low-cost, instrument-free test for measuring CD4 T-cell count in HIV/AIDS patients

US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE(R) Smallpox Vaccine

KVISTGÅRD, Denmark, November 17 - Bavarian Nordic A/S (OMX: BAVA) announced today that BARDA (Biomedical
Advanced Research and Development Authority) has awarded a new contract to
Bavarian Nordic for the development of a freeze-dried version of its
IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40
million.

Frost & Sullivan Reveals Strategies on Turning Challenges into Opportunities in the European Biomarkers Market

LONDON, November 16 - The "omics" revolution of the last decade has ensured that the field of
biomarker research will test the frontiers of biomedical research in the
coming years. New biomarkers are discovered each day and this rapid
development promises excellent growth potential for the biomarker analysis
market. However, due to various challenges faced in biomarker validation and
assay development, there is a huge lag between the time that a biomarker is
discovered in the laboratory and the time it is actually commercialized.

Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics

Presentation highlights Palomid 529 as a first-in-class dual TORC1/TORC2 inhibitor in Brain Cancer -

ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours

LEUVEN, Belgium and LUND, Sweden, November 16 - ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) today announced positive results from a Phase I
trial of their novel anti-cancer monoclonal antibody TB-403 in patients with
advanced solid tumours. The results were presented at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics in
Boston, U.S. TB-403 was well tolerated with no reported dose limiting
toxicity. These positive data support progression of TB-403 and further
development.

Bluestar Silicones to Make its Debut at MEDICA 2009 in Düsseldorf to Showcase the Silbione(R) Difference

LYON, France, November 12 - Bluestar Silicones will make its debut at MEDICA 2009 in Düsseldorf to
showcase its innovative and skin-friendly Silbione(R) range of silicones
products.

Health Robotics Reaches 100% Asia-Pacific Coverage Through its New Exclusive Distribution Contract With BioRobotics in Korea

BOZEN, SUD-TYROL, Italy, November 12 - Health Robotics today announced that Innomed/BioRobotics, on the heels of
its prior market success with Oncology Surgery robots, has exclusively
selected Health Robotics' CytoCare(TM) Robot to reach its objective to become
the gold standard for Oncology Robotics IV Admixtures in the Republic of
Korea and synergistically provide an end-to-end Cancer Robotics solution.

Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference

Favorable safety and pharmacokinetic data support further clinical development

AMT Successful in Preclinical Treatment of DMD

AMSTERDAM, November 11 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, announced today that it has successfully
treated Duchenne muscular dystrophy (DMD) in an animal model with its
proprietary gene therapy. The proof of concept studies were performed in
collaboration with the group of Professor Irene Bozzoni (University of Rome,
La Sapienza, Italy) and demonstrated effectiveness in the heart as well as in
skeletal muscles. In a previous study, AMT's gene therapy approach was shown
to be successful in the treatment of diseased human muscle cells obtained
from biopsies of DMD patients. These data establish a robust basis for AMT's
therapeutic approach to DMD.

Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009

KVISTGARD, Denmark, November 11 - Today Bavarian Nordic published the company's third quarterly report
2009. The full report including the financial statements is available on the
company's website: www.bavarian-nordic.com.

Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment

LONDON - Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited (www.davalinternational.com) has been informed that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS).

intendiX - Communication by Thoughts: First Patient-Ready System on the Market

SCHIEDLBERG, Austria - For more than 20 years researchers all over the world have been working on the development of a Brain-Computer Interface (BCI). This is a direct communication channel between the brain and a computer. Such a system enables completely paralyzed patients to communicate or to control devices in their environment just by mental activity. During the last years some patients have been supervised by the researchers themselves to use such BCI systems in daily life. The Austrian company g.tec medical engineering GmbH now brings the first patient-ready BCI on the market. The EEG-based spelling system is called intendiX and enables the user to select keys from a matrix just by paying attention to a target symbol on the screen.

D-Pharm Enters Into Collaboration With Wanbang Biopharmaceuticals to Increase the Potential Market for its Stroke Drug-Candidate DP-b99

REHOVOT, Israel - D-Pharm Ltd. (TASE: DPRM) announced today that it has entered into a licensing, co-development and supply agreement with Wanbang Biopharmaceuticals Ltd. for commercialization of DP-b99 in the People’s Republic of China. DP-b99 is a novel drug discovered and developed by D-Pharm for treatment of patients with acute ischemic stroke. DP-b99, designated as an Investigational New Drug (IND) in the US, is currently in a Phase III multinational clinical study (study acronym: MACSI).

Haft Group says Bullish Commodity Market Triggers Small and Micro-cap Upsurge

NEW YORK -

“Micro cap and small cap equities across the board, are struggling to receive more broker sponsorship and exposure as a ‘buying window’ opens and to take advantage of the upturn in commodity-driven stocks like gold, silver and other metals,” states Herbert Haft, President of The Haft Group, Inc, Manhattan based investor relations firm with a focus on the micro cap and small cap equities market in the US and Canada, and with expansion plans into the UK and China.

Novartis to Acquire Majority Stake in Hard to Treat Diseases’ (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million

SHENZHEN, China - Hard To Treat Diseases (OTC: HTDS) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS’ H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million. Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one of its top three markets worldwide. The comments were made by Novartis’ CEO, Daniel Vasella, in an interview with The Wall Street Journal. www.chinabiotoday.com/articles/20091103_1

Sirius Genomics received NRC-IRAP Funding for Continued Development of a Sepsis Companion Diagnostic

VANCOUVER - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed its first Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This research funding will be used to study genomic correlations in severe sepsis patients. Specifically, the contribution will go towards the continued development of Sirius’ pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated Protein C (developed and marketed by Eli Lilly and Company under the trademark Xigris (R)) in patients with severe sepsis at high risk of death.

Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts

AURORA, Ontario -

Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: HXBPF) announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.

ThromboGenics NV - Q3 2009 Business Update

LEUVEN, Belgium - ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease

CAMBRIDGE, Massachusetts -

- FDA Issued Action Date of February 28, 2010 Under the Prescription Drug User Free Act (PDUFA)

Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas

BOZEN, Italy - Health Robotics today announced the worldwide presentation and launch of its new i.v.SOFT Workflow Engine at the American Society of Health-System Pharmacists’ Mid-Year Meeting December 6-10 in Las Vegas. With the availability of the i.v.SOFT Workflow Engine, Health Robotics becomes the first and only company in the world to provide a total automation solution to fill the void of automated process control and patient safety in the I.V. Room.

Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health

PETERSBURG, Virginia -

Star Scientific, Inc. (Nasdaq: STSI) announced today that the company plans to introduce the CigRx(TM) nutraceutical product developed by its subsidiary, Rock Creek Pharmaceuticals, for worldwide marketing and sales in partnership with inVentiv Health, Inc. (Nasdaq: VTIV). inVentiv Health offers a complete range of commercialization solutions for every stage of the product lifecycle, in a range of healthcare categories that includes nutraceutical products. The company has marketing and sales capabilities in 40 countries around the globe. Jonnie R. Williams, Star’s CEO, stated, “Cigarette smoking is the leading cause of preventable death in the world. However, the global cigarette business, which now exceeds US$300 billion, continues to grow. Our goal is to make CigRx(TM) available to adult smokers worldwide who wish to maintain a nicotine-free metabolism.” Rock Creek Pharmaceuticals will be responsible for the manufacturing of CigRx(TM), and the company anticipates that inVentiv Health will be involved in the product marketing and sales, with a focus on product education for physicians and health care professionals, as well as consumers.

Ortho Clinical Diagnostics Launches First-of-its-kind Remote Monitoring Center in Europe

PARIS -

- 24 Hour Central Command Center now Offers Predictive and Proactive Diagnostic Monitoring Service in Eight Languages to Clinical Laboratories in 18 Countries Using VITROS(R) Systems

MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014

WILMINGTON, Delaware - The new market research report, ‘Global Stem Cell and Advanced Technologies Market’ (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com) analyzes the major trends in the global stem cell market. It identifies and analyzes the main market drivers, restraints, and opportunities for the various products, services, technologies, and applications submarkets in different geographic regions.